Inventor · disambiguated record
Irina C. Jacobson
Also filed as: JACOBSON IRINA · JACOBSON IRINA C · JACOBSON IRINA CIPORA
32 granted patents·6 pending applications·428 citations·filing 1993–2022
97Inventor score
Files withCOCRYSTAL PHARMA INC11BRISTOL MYERS SQUIBB PHARMA CO7DU PONT MERCK PHARMA4COCRYSTAL DISCOVERY INC3DU PONT PHARM CO3
Top patents by PatentIndex Score
38 records- 0195US6399644B1Aryl sulfonyls as factor XA inhibitorsFiled 2000·Granted Jun 4, 2002·46 cites·15 claims
- 0292US6689770B2Aryl sulfonyls as factor Xa inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2002·Granted Feb 10, 2004·29 cites·18 claims
- 0391US8771665B2Inhibitors of hepatitis C virus polymeraseLEE SAM S K·Filed 2011·Granted Jul 8, 2014·13 cites·13 claims
- 0491US6710058B2Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Mar 23, 2004·28 cites·23 claims
- 0591US6429205B1Nitrogen containing heterobicycles as factor Xa inhibitorsBRISTOL MEYERS SQUIBB PHARMA C·Filed 2000·Granted Aug 6, 2002·32 cites·21 claims
- 0690US6602871B2Thrombin or factor Xa inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Aug 5, 2003·20 cites·24 claims
- 0787US11014941B2Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replicationCOCRYSTAL PHARMA INC·Filed 2018·Granted May 25, 2021·4 cites·20 claims
- 0886US6716841B2Nitrogen containing heterobicycles as factor Xa inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2002·Granted Apr 6, 2004·24 cites·18 claims
- 0985US8338477B2Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefitsDUNCAN IAIN W·Filed 2009·Granted Dec 25, 2012·16 cites·19 claims
- 1084US6951872B2Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitorsBRISTOL MYERS SQUIBB PHARMA CO·Filed 2003·Granted Oct 4, 2005·14 cites·21 claims
- 1184US5639759ACarbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agentsDU PONT MERCK PHARMA·Filed 1995·Granted Jun 17, 1997·46 cites·16 claims
- 1283US10947210B2Inhibitors of Hepatitis C virus polymeraseCOCRYSTAL PHARMA INC·Filed 2019·Granted Mar 16, 2021·2 cites·8 claims
- 1383US10464914B2Inhibitors of hepatitis C virus polymeraseCOCRYSTAL PHARMA INC·Filed 2016·Granted Nov 5, 2019·5 cites·21 claims
- 1481US5703092AHydroxamic acid compounds as metalloprotease and TNF inhibitorsDU PONT MERCK PHARMA·Filed 1996·Granted Dec 30, 1997·58 cites·11 claims
- 1577US6403583B1Thrombin or factor Xa inhibitorsFiled 1999·Granted Jun 11, 2002·17 cites·27 claims
- 1673US9707215B2Inhibitors of hepatitis C virus polymeraseCOCRYSTAL DISCOVERY INC·Filed 2013·Granted Jul 18, 2017·3 cites·10 claims
- 1772US5874441ACarbocyclic and hetertocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agentsDU PONT PHARM CO·Filed 1997·Granted Feb 23, 1999·23 cites·19 claims
- 1868US6110910ACarbocyclic heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agentsDU PONT PHARM CO·Filed 1998·Granted Aug 29, 2000·18 cites·16 claims
- 1962US6878710B2Bicyclic inhibitors of factor XaBRISTOL MYERS SQUIBB PHARMA CO·Filed 2002·Granted Apr 12, 2005·2 cites·40 claims
- 2060US2024398757A1Inhibitors for coronavirusesCOCRYSTAL PHARMA INC·Filed 2022·Application pending·0 cites
- 2159US5428040ACarbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agentsDU PONT MERCK PHARMA·Filed 1993·Granted Jun 27, 1995·10 cites·8 claims
- 2258US6790845B2Fused heterocyclic inhibitors of factor XaBRISTOL MYERS SQUIBB PHARMA CO·Filed 2002·Granted Sep 14, 2004·1 cites·37 claims
- 2356US2023159453A1Inhibitors of norovirus and coronavirus replicationCOCRYSTAL PHARMA INC·Filed 2021·Application pending·0 cites
- 2455US2023131564A1Inhibitors of norovirus and coronavirus replicationCOCRYSTAL PHAEMA INC·Filed 2021·Application pending·0 cites
- 2555US2014322165A1Inhibitors of hepatitis c virus polymeraseCOCRYSTAL DISCOVERY INC·Filed 2014·Application pending·0 cites
- 2654US12233066B2Combinations of inhibitors of influenza virus replicationCOCRYSTAL PHARMA INC·Filed 2019·Granted Feb 25, 2025·0 cites·20 claims
- 2754US9896422B2Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefitsNeumedics·Filed 2017·Granted Feb 20, 2018·0 cites·20 claims
- 2854US9168265B2Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefitsNeumedics·Filed 2012·Granted Oct 27, 2015·0 cites·6 claims
- 2952US12357631B2Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replicationCOCRYSTAL PHARMA INC·Filed 2019·Granted Jul 15, 2025·0 cites·19 claims
- 3051US11752166B2Combination therapy for treatment of HCVCOCRYSTAL PHARMA INC·Filed 2019·Granted Sep 12, 2023·0 cites·19 claims
- 3151US2023151034A1Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replicationCOCRYSTAL PHARMA INC·Filed 2021·Application pending·0 cites
- 3250US12156876B2Formulations of influenza therapeuticsCOCRYSTAL PHARMA INC·Filed 2019·Granted Dec 3, 2024·0 cites·19 claims
- 3350US9573912B2Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefitsNeumedics·Filed 2015·Granted Feb 21, 2017·0 cites·20 claims
- 3450US6281352B1Macrocyclic compounds as metalloprotease inhibitorsDU PONT PHARM CO·Filed 1997·Granted Aug 28, 2001·10 cites·50 claims
- 3547US5691381AHydroxamic and carbocyclic acids as metalloprotease inhibitorsDU PONT MERCK PHARMA·Filed 1996·Granted Nov 25, 1997·7 cites·4 claims
- 3646US12037333B2Pyridopyrazine and pyridotriazine inhibitors of influenza virus replicationCOCRYSTAL PHARMA INC·Filed 2019·Granted Jul 16, 2024·0 cites·22 claims
- 3746US10426762B2Inhibitors of hepatitis C virus polymeraseCOCRYSTAL DISCOVERY INC·Filed 2017·Granted Oct 1, 2019·0 cites·8 claims
- 3842US2008234271A1Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing ThemICOS CORP·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →